TABLE 1.
Demographics of study participants
| All participants (n=21) | IV ABx (n=12) | Oral ABx (n=9) | p-value# | |
|---|---|---|---|---|
| Age, years, mean (range) | 13.3 (8.0–17.0) | 13.8 (8.0–17.0) | 12.5 (8.7–16.7) | 0.33 |
| Male, n (%) | 8 (38) | 3 (25) | 5 (55) | 0.26 |
| Pancreatic insufficiency, n (%) | 18 (85) | 11 (91) | 7 (78) | 0.73 |
| ppFEV1, mean (sd) | ||||
| Before ABx | 64.6 (14.9) | 60.2 (8.9) | 70.4 (19.6) | 0.04 |
| After ABx | 77.6 (13.8) | 72.2 (10.8) | 84.8 (14.8) | 0.03 |
| Microbiology , n | ||||
| Staphylococcus aureus | 9 | 4 | 5 | |
| Staphylococcus aureus and Haemophilus influenzae | 6 | 2 | 4 | |
| Staphylococcus aureus and Pseudomonas aeruginosa | 3 | 3 | 0 | |
| Pseudomonas aeruginosa | 3 | 3 | 0 | |
#: p-values represent comparison between intravenous (IV) antibiotic (ABx) and oral ABx therapy groups. An unpaired t-test or Wilcoxon test was used for group comparisons. ppFEV1: precent predicted forced expiratory volume in 1 s.